Reviva Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the target of unusually large options trading on Wednesday. Traders bought 3,065 call options on the company. This represents an increase of approximately 235% compared to the typical daily volume of 915 call options.

Institutional Trading of Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC lifted its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 278,496 shares of the company’s stock after buying an additional 42,376 shares during the quarter. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Maxim Group restated a “hold” rating on shares of Reviva Pharmaceuticals in a research note on Friday, August 16th. Benchmark reissued a “speculative buy” rating and set a $17.00 price objective on shares of Reviva Pharmaceuticals in a research report on Monday, August 26th. Finally, EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd.

Reviva Pharmaceuticals Stock Down 1.6 %

Shares of NASDAQ:RVPH opened at $2.77 on Friday. The company has a market cap of $92.63 million, a price-to-earnings ratio of -2.50 and a beta of -0.02. Reviva Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $5.67. The firm’s 50-day simple moving average is $1.30 and its 200-day simple moving average is $1.23.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.